CANAGLIFLOZIN SILICA LIPID HYBRID PARTICLES FOR IMPROVED SOLUBILITY AND DISSOLUTIONAbstract
Silica lipid-hybrid formulations have gained an increased interest in recent times as a means to enhance the solubility as well as dissolution of poorly water-soluble lipophilic drugs. The objective of the present investigation was to design and optimize silica lipid hybrid particles of Canagliflozin to improve its solubility. Canagliflozin is an antidiabetic drug used to improve glycaemic control in people with type 2 diabetes. In this study, we have fabricated a Solid-State Lipid-Based Oral Drug Delivery System as CNZ SLH with liquid lipids like Miglyol 812, Labrasol and Acrysol el 135. Sylloid 244 FP grade highly porous silica was used as adsorbent. The interaction of CNZ-SLH particles was studied using X-ray powder diffraction (PXRD), Differential Scanning Calorimetry (DSC) and FTIR spectroscopy. CNZ-SLH particles prepared with Miglyol and Labrasol enhanced the solubility of CNZ by 19.67 fold. Optimized SLH particles formulated as a tablet shows faster drug release than the marketed formulation of CNZ Invokana. Silica lipid hybrid particles can be a cost-effective method to formulate drugs with poor solubility.
S. S. Tiwari * and S. J. Wadher
Indira College of Pharmacy, Sahyog Campus, Vishnupuri, Nanded, Maharashtra, India.
12 December 2019
29 January 2020
03 February 2020
01 March 2020